Insider Buying: Burning Rock Biotech (NASDAQ:BNR) Director Acquires $1,942,500.00 in Stock

Posted by Francis Steltz on Jul 5th, 2026

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR – Get Free Report) Director Yusheng Han purchased 210,000 shares of the stock in a transaction on Friday, June 12th. The stock was bought at an average price of $9.25 per share, for a total transaction of $1,942,500.00. Following the completion of the transaction, the director directly owned 17,907,436 shares of the company’s stock, valued at approximately $165,643,783. This trade represents a 1.19% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Yusheng Han also recently made the following trade(s):

On Friday, June 26th, Yusheng Han acquired 24,900 shares of Burning Rock Biotech stock. The shares were bought at an average price of $8.00 per share, with a total value of $199,200.00.
On Wednesday, June 24th, Yusheng Han acquired 250,000 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $8.00 per share, with a total value of $2,000,000.00.
On Tuesday, June 23rd, Yusheng Han bought 5,990 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $7.50 per share, for a total transaction of $44,925.00.
On Monday, June 22nd, Yusheng Han bought 104,650 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $7.45 per share, for a total transaction of $779,642.50.
On Tuesday, June 16th, Yusheng Han bought 111,110 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $9.00 per share, for a total transaction of $999,990.00.
On Thursday, June 11th, Yusheng Han bought 24,760 shares of Burning Rock Biotech stock. The shares were purchased at an average price of $8.74 per share, with a total value of $216,402.40.

Burning Rock Biotech Stock Performance

Shares of BNR stock opened at $9.82 on Friday. Burning Rock Biotech Limited Sponsored ADR has a 12-month low of $3.23 and a 12-month high of $41.72. The company has a market capitalization of $103.31 million, a P/E ratio of -11.98 and a beta of 1.32. The firm has a 50-day moving average price of $12.35 and a 200 day moving average price of $19.96. The company has a quick ratio of 2.81, a current ratio of 3.05 and a debt-to-equity ratio of 0.06.

Burning Rock Biotech (NASDAQ:BNR – Get Free Report) last issued its quarterly earnings data on Tuesday, June 9th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($2.29) by $2.09. The firm had revenue of $15.66 million for the quarter, compared to analysts’ expectations of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Wall Street Analyst Weigh In

A number of research firms recently commented on BNR. Wall Street Zen lowered Burning Rock Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Burning Rock Biotech presently has an average rating of “Sell”.

Read Our Latest Stock Analysis on BNR

Institutional Trading of Burning Rock Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Marshall Wace LLP bought a new position in Burning Rock Biotech in the 4th quarter worth approximately $220,000. Prospera Financial Services Inc boosted its position in Burning Rock Biotech by 26.0% in the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after buying an additional 6,430 shares during the last quarter. Renaissance Technologies LLC boosted its position in Burning Rock Biotech by 13.8% in the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after buying an additional 4,290 shares during the last quarter. Finally, Crcm LP increased its stake in shares of Burning Rock Biotech by 13.8% in the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after buying an additional 26,809 shares during the period. Institutional investors and hedge funds own 30.03% of the company’s stock.

About Burning Rock Biotech

(Get Free Report)

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.